Long-term effect of interferon treatment on the progression of chronic hepatitis B: Bayesian meta-analysis and meta-regression

Hepatology Research

Volumn 41, Issue 6, 2011, Pages 512-523

  Jin, Hui ^a   Pan, Ning ^a   Mou, Yi ^b   Wang, Bei ^a   Liu, Pei ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Bayesian meta analysis; Bayesian meta regression; Chronic hepatitis B; Disease progression; Interferon

Indexed keywords

ALPHA INTERFERON; ALPHAN1 INTERFERON; BETA INTERFERON; INTERFERON; VIRUS DNA;

ARTICLE; BAYES THEOREM; CHRONIC HEPATITIS; DEATH; DISEASE COURSE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS HEPATITIS;

EID: 79957538243     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00801.x     Document Type: Article

References (42)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
2. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10: 1-183.
3. Oon CJ. Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992; 31 (Suppl): S137-42.
4. Mazzella G, Accogli E, Sottili S etal. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24: 141-7.
5. Niederau C, Heintges T, Lange S etal. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7.
6. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26: 1338-42.
7. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998; 83: 901-9.
8. Brunetto MR, Oliveri F, Koehler M, Zahm F, Bonino F. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535-9.
9. Ikeda K, Saitoh S, Suzuki Y etal. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus - a pilot study. Cancer 1998; 82: 827-35.
10. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. J Viral Hepat 1998; 5: 389-97.
11. Di Marco V, Lo IO, Camma C etal. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257-64.
12. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5.
13. Mazzella G, Saracco G, Festi D etal. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999; 94: 2246-50.
14. Fujisawa T, Komatsu H, Inui A etal. Long-term outcome of chronic hepatitis B in adolescents or young adults in follow-up from childhood. J Pediatr Gastr Nutr 2000; 30: 201-6.
15. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306-13.
16. Tangkijvanich P, Thong-ngam D, Mahachai V, Kladchareon N, Suwangool P, Kullavanijaya P. Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B. Southeast Asian J Trop Med Public Health 2001; 32: 452-8.
17. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-45.
18. Mahmood S, Niiyama G, Kamei A etal. Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int 2005; 25: 220-5.
19. Truong BX, Seo Y, Kato M etal. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. Int J Mol Med 2005; 16: 279-84.
20. Lin SM, Yu ML, Lee CM etal. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52.
21. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593-602.
22. Craxi A, Di Bona D, Interferon-alpha CC. for HBeAg-positive chronic hepatitis B. J Hepatol 2003; 39 (Suppl 1): S99-105.
23. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-77.
24. Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 2009; 44: 470-5.
25. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009; 16: 265-71.
26. Sharp SJ, Thompson SG. Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches. Stat Med 2000; 19: 3251-74.
27. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-73.
28. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 2003; 73: 712-16.
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
30. de Boer AG, Taskila T, Ojajarvi A, van Dijk FJ, Verbeek JH. Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA 2009; 301: 753-62.
31. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
32. Congdon P. Applied Bayesian Modelling. Chichester: Wiley, 2003.
33. Vetencourt R, Vetencourt M, De Armas J. Longitudinal follow-up study of 64 children chronically infected with hepatitis B virus, treated and not treated with interferon. Gen 1995; 49: 227-33.
34. Brunetto MR, Oliveri F, Coco B etal. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-70.
35. Lin SM, Tai DI, Chien RN, Sheen IS, Chu CM, Liaw YF. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat 2004; 11: 349-57.
36. Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004; 19: 670-5.
37. Lin SM, Yu ML, Lee CM etal. Interferon therapy reduces cirrhosis and hepatocellular carcinoma in HBeAg positive chronic hepatitis B. J Hepatol 2006; 44: S23.
38. Chen XY, Yu YY, Ma LN etal. [Effects of antiviral effects of agents and prognosis of chronic hepatitis B]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2006; 20: 219-22.
39. Iorio R, Giannattasio A, Cirillo F, D AL, Vegnente A. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis 2007; 45: 943-9.
40. Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: A critical event in chronic hepatitis B virus infection. Dig Dis Sci 2010; 55: 2727-34.
41. Fried MW, Piratvisuth T, Lau GK etal. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428-34.
42. Borenstein M. Introduction to Meta-Analysis. Chichester: John Wiley & Sons, 2009.